Abstract
Mammalian target of rapamycin (mTOR) inhibitors represent a new class of potential anticancer agents. The mTOR inhibitor, rapamycin, inhibited proliferation in three mantle cell lymphoma (MCL) cell lines and reduced cyclin D3 expression while cyclin D1 levels remained unchanged. This finding was confirmed in cells from a MCL patient.
Publication types
-
Comparative Study
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Cell Cycle / drug effects*
-
Cell Cycle / physiology
-
Cell Line, Tumor
-
Drug Delivery Systems / methods
-
Humans
-
Lymphoma, Mantle-Cell / drug therapy*
-
Lymphoma, Mantle-Cell / metabolism
-
Lymphoma, Mantle-Cell / pathology*
-
Protein Kinases* / biosynthesis
-
Protein Kinases* / metabolism
-
Sirolimus / administration & dosage*
-
TOR Serine-Threonine Kinases
Substances
-
Protein Kinases
-
MTOR protein, human
-
TOR Serine-Threonine Kinases
-
Sirolimus